Wuxi AppTec’s chemical business doubled last year, but only grew around 40% excluding revenue from Covid-related products and services. The drug outsourcing services company’s net profit fell 47.6% ...

SHANGHAI, June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science ...

SHANGHAI, June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science ...

SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies ...

SHANGHAI, May 15, 2017 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has ...

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a ...

SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science ...

SHANGHAI, Feb 5 (Reuters) - A draft U.S. bill that has triggered a sell-off in shares of China's biotech firm Wuxi Apptec could deal a major blow not just to the firm but could also impact many labs ...

NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced an expanded partnership with WuXi ...

ET Net News Agency, 27 February 2026] A direct manual trade of 258,500 shares of WUXI APPTEC (02359) was registered at 2:44p.m. The deal amounted to HK$30.54m, or at HK$118.15 pe ...